Literature DB >> 2527546

Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients.

O G Nilsen1, O F Sellevold, O S Romfo, A Smedsrud, B Grynne, P E Williams, C H Kleinbloesem.   

Abstract

1. Possible interactions between cilazapril and hydrochlorothiazide with respect to pharmacokinetics and renal effects were investigated in healthy subjects (single dose) and in hypertensive patients (multiple dosing). 2. No significant pharmacokinetic interaction was found between cilazapril and hydrochlorothiazide. 3. Cilazapril showed weak saluretic properties as compared with hydrochlorothiazide, but increased the saluretic effects of hydrochlorothiazide. 4. Cilazapril attenuated the hypokalaemia observed with hydrochlorothiazide in hypertensive patients. 5. The effect on blood pressure reduction obtained from the combination of cilazapril and hydrochlorothiazide lasted longer than that of cilazapril alone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2527546      PMCID: PMC1379765          DOI: 10.1111/j.1365-2125.1989.tb03499.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.

Authors:  R J Francis; A N Brown; L Kler; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

2.  Simple and selective high-performance liquid chromatographic method for the determination of hydrochlorothiazide in urine.

Authors:  G K Shiu; V K Prasad; J Lin; W Worsley
Journal:  J Chromatogr       Date:  1986-04-25

Review 3.  Role of angiotensin converting enzyme inhibitors in essential and renal hypertension. Effects of captopril and enalapril on renin-angiotensin-aldosterone, renal function and hemodynamics, salt and water excretion, and body fluid composition.

Authors:  J H Bauer
Journal:  Am J Med       Date:  1984-08-20       Impact factor: 4.965

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

5.  Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.

Authors:  T Fasanella d'Amore; J P Bussien; J Nussberger; B Waeber; G A Turini; H R Brunner; L Kler; R J Francis
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

  5 in total
  7 in total

1.  The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.

Authors:  E J Begg; R A Robson; R R Bailey; K L Lynn; G J Frank; S C Olson
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 2.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 3.  Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.

Authors:  F Deget; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 4.  Clinical pharmacology of cilazapril.

Authors:  C H Kleinbloesem; P van Brummelen; R J Francis; U W Wiegand
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 5.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 6.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

7.  Potential drug-drug interactions in the medication of medical patients at hospital discharge.

Authors:  Sabin S Egger; Jürgen Drewe; Raymond G Schlienger
Journal:  Eur J Clin Pharmacol       Date:  2003-02-21       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.